Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 7/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462281 | 1.00 | USP30 (0.54) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL1462278 | 1.00 | USP30 (0.54) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL1560305 | 0.95 | USP30 (0.50) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL1464083 | 0.93 | USP30 (0.52) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL1464084 | 0.93 | USP30 (0.52) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL1464082 | 0.93 | USP30 (0.52) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL12716154 | 0.92 | MGLL (0.48) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL1462934 | 0.88 | USP30 (0.56) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL1462939 | 0.88 | USP30 (0.56) | USP30CLK1NPY5RHCRTR1HCRTR2 | |
| SCHEMBL1462937 | 0.88 | USP30 (0.56) | USP30CLK1NPY5RHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207220-B2 | Substituted benzothiazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-06-26 | — | — | US | claimed |
| EP-2303871-B1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | claimed |
| JP-2011529096-A | — | — | 2011-12-01 | — | — | JP | claimed |
| EP-2303871-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-04-06 | — | — | EP | claimed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | claimed |
| WO-2010012620-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | claimed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | claimed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8207220-B2 | Substituted benzothiazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2303871-B1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | USP30 4253/4885CLK1 4628/4885NPY5R 11/4885 |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | USP30 4253/4885CLK1 4628/4885NPY5R 11/4885 |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | USP30 4253/4885CLK1 4628/4885NPY5R 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.